Article
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2009
Ogino Shuji, Meyerhardt Jeffrey A, Irahara Natsumi, Niedzwiecki Donna, Hollis Donna, Saltz Leonard B, Mayer Robert J, Schaefer Paul, Whittom Renaud, Hantel Alexander, Benson Al B, Goldberg Richard M, Bertagnolli Monica M, Fuchs Charles S
Abstract excerpt
PURPOSE: Alterations in the RAS and RAF pathway relate to epigenetic and epigenomic aberrations, and are important in colorectal carcinogenesis. KRAS mutation in metastatic colorectal cancer predicts resistance to anti-epidermal growth factor receptor (EGFR)-targeted therapy (cetuximab or panitumumab). It remains uncertain, however, whether KRAS mutation predicts prognosis or clinical outcome of colon cancer...
Topics
- Adult
- Aged
- Antineoplastic Agents
- Camptothecin
- Colonic Neoplasms
- Disease-Free Survival
- Female
- Genes, ras
- Humans
- Irinotecan